SCHEMBL8924430

SCHEMBL8924430

Brc1cc(OCc2ccccc2)c(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.53
KDM1A O60341 2/20 0.51
MAPT P10636 2/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
SLC6A4 P31645 1/20 0.50
MAPK1 P28482 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
THRA P10827 1/20 0.47
THRB P10828 1/20 0.47
CCR5 P51681 1/20 0.47
HTR1A P08908 1/20 0.46
DRD2 P14416 1/20 0.46
RAB9A P51151 2/20 0.46
USP28 Q96RU2 1/20 0.46
USP25 Q9UHP3 1/20 0.46
ALDH1A1 P00352 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128840 0.84 ABCB1 (0.52) MAPTGAATDP1THRBHTR1A
SCHEMBL5839199 0.84 FOLH1 (0.56) L3MBTL1THRATHRBALDH1A1SMN1; SMN2
SCHEMBL28598401 0.82 GAA (0.65) MAOBMAPTGAAHPGDTHRA
SCHEMBL2090373 0.82 LMNA (0.52) MAPTGAAHPGDMAPK1TDP1
SCHEMBL15869787 0.81 MAPT (0.58) MAPTGAAHPGDMAPK1TDP1
SCHEMBL368071 0.81 SLC6A4 (0.66) MAOBSLC6A4CCR5RAB9AUSP28
SCHEMBL2094089 0.81 MAPT (0.48) MAPTHPGDMAPK1TDP1L3MBTL1
SCHEMBL11133548 0.81 MAOB (0.53) MAOBMAPTGAAMAPK1TDP1
SCHEMBL2090370 0.81 MAPT (0.48) MAOBMAPTHPGDMAPK1TDP1
SCHEMBL31644088 0.81 SLC6A4 (0.66) MAOBSLC6A4CCR5RAB9AUSP28

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES, INC. 2024-10-10 US disclosed
WO-2023288020-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES INC. (US) 2023-01-19 WO disclosed
WO-2023288020-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES INC. (US) 2023-01-19 WO disclosed
US-8188144-B2 In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells ANTOXIS LIMITED (GB) 2012-05-29 US disclosed
US-20100267132-A1 IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS ANTOXIS LIMITED (GB) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS MPO, GPX4, GPX1 MAOB 806/4885KDM1A 2578/4885MAPT 1586/4885
US-20100267132-A1 IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS PIGS, AQP1, F12 MAOB 2253/4885KDM1A 801/4885MAPT 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.